BenevolentAI
the business model leveraging our technology platform to generate new drug at scale in house pipeline discovery tools develop and owned in house pipeline of novel discovery stage assets taken to out at end phase i or end phase milestones royalties decision criteria feasibility of mid and late stage clinical development size specialism fit with emerging model funding environment platform collaborations selective platform collaborations which can leverage the platform in areas outside our core competencies economic bene platform validation data generated enriches the platform | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
December 2021
Slide
32 of 42
Similar slides by BenevolentAI
See diffirences between slides (animation)
Results
March 2023
our business model unlocks multiple routes to value creation discovery tools owned pipeline platform generated assets in house development licensing platform generated assets out licensed at end phase i or end platform collaborations economic bene platform validation data generated enriches the benevolent non commercial collaborations platform validation data generated enriches the benevolent flexible | BenevolentAI
Investor Conference
January 2023
our business model unlocks multiple routes to value creation flexible | BenevolentAI
Investor Conference
November 2022
in house pipeline the business model leveraging our technology platform to generate new drug at scale decision criteria develop in house out license at end phase i or end phase milestones royalties collaborations selective platform collaborations which can leverage the platform in areas outside our core competencies economic bene platform validation data generated enriches the benevolent non commercial collaborations covid platform validation data generated enriches the benevolent | BenevolentAI
Investor Presentation
October 2022
in house pipeline the business model leveraging our technology platform to generate new drug at scale decision criteria develop in house out license at end phase i or end phase milestones royalties collaborations selective platform collaborations which can leverage the platform in areas outside our core competencies economic bene platform validation data generated enriches the benevolent non commercial collaborations covid platform validation data generated enriches the benevolent | BenevolentAI
Related slides by other companies
GitLab
Results
December 2022
| GitLab
Akouos
IPO
June 2020
deep pipeline highlights breadth of platform | Akouos
Akouos
IPO
June 2020
deep pipeline highlights breadth of platform | Akouos
Akouos
IPO
June 2020
deep pipeline highlights breadth of platform | Akouos
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io